Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
BUSINESS Arexvy Already January GP Rep Promotion Champion, Tarlige Tops HP Ranking
March 21, 2024
-
BUSINESS SanBio Chief Baffled by Planned Advisory Session over Lead Cell Therapy
March 21, 2024
-
ORGANIZATION Shipments Restricted or Halted for 26.6% of Drugs in February: FPMAJ
March 21, 2024
-
BUSINESS JCR Hits 1st Milestone in Alexion Collab for Neurodegenerative Disease
March 21, 2024
-
REGULATORY Industry Explains Scheme to Deal with New Self-Inspection Asked for All Generic Makers
March 19, 2024
-
REGULATORY Japan Mulls Simplifying Drug Delisting Process to Help Ensure Stable Supplies
March 19, 2024
-
BUSINESS Shonan iPark Launches Local Post in South Korea
March 19, 2024
-
ORGANIZATION Biosafety Rules Tied to Gene Therapy Put Heavy Financial Burden on Hospitals: Expert
March 19, 2024
-
REGULATORY Japan to Work towards Ensuring Consistency in Different Clinical Trial Laws
March 19, 2024
-
REGULATORY Japan Panel to Discuss Fate of SanBio’s Sakigake Cell Therapy amid Stalled Review
March 19, 2024
-
BUSINESS ASKA Ties Up with Red Arrow on Novel Preeclampsia Treatment
March 19, 2024
-
BUSINESS Canaglu OD Tablet Version Approved in Japan
March 19, 2024
-
BUSINESS FY2024 Revision Rates Tallied for Each Firm’s Top 5 Meds; Fuso Logs Price Hike Too on Infusion Products
March 18, 2024
-
BUSINESS Sumitomo Offloads Entire Ulotaront Rights to Otsuka for Strategic Priorities
March 18, 2024
-
ORGANIZATION Doctors’ Groups Call for Cross-Ministerial Efforts to Spur Genomic Medicine
March 18, 2024
-
ACADEMIA Lecanemab Combo Trial Launched in Japan for Familial Alzheimer’s
March 18, 2024
-
REGULATORY Japan to Cap COVID Vaccine Copay at 7,000 Yen under NIP
March 18, 2024
-
BUSINESS BIKEN’s 5-in-1 Vaccine Reaches Market Too before NIP Inclusion
March 18, 2024
-
BUSINESS Daiichi Sankyo Offers Hefty 7%-Plus Pay Hike in 2024
March 18, 2024
-
BUSINESS Bimzelx’s 320 mg Auto-Injector Version Filed in Japan: UCB
March 18, 2024
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…